DrugPatentWatch Database Preview
Details for Patent: 8,080,580
Which drugs does patent 8,080,580 protect, and when does it expire?
Patent 8,080,580 protects SEGLUROMET, STEGLATRO, and STEGLUJAN, and is included in three NDAs.
This patent has fifty-six patent family members in forty-six countries.
Summary for Patent: 8,080,580
| Title: | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
| Abstract: | Compounds of Formula (I) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors). ##STR00001## |
| Inventor(s): | Mascitti; Vincent (Groton, CT), Collman; Benjamin M. (Ledyard, CT) |
| Assignee: | Pfizer Inc. (New York, NY) |
| Application Number: | 12/546,306 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Compound; |
Drugs Protected by US Patent 8,080,580
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-002 | Dec 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | Start Trial | ||
| Merck Sharp Dohme | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-001 | Dec 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | Start Trial | ||
| Merck Sharp Dohme | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-004 | Dec 19, 2017 | RX | Yes | Yes | Start Trial | Start Trial | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | Start Trial | ||
| Merck Sharp Dohme | SEGLUROMET | ertugliflozin; metformin hydrochloride | TABLET;ORAL | 209806-003 | Dec 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | Start Trial | ||
| Merck Sharp Dohme | STEGLATRO | ertugliflozin | TABLET;ORAL | 209803-001 | Dec 19, 2017 | RX | Yes | No | Start Trial | Start Trial | Y | Y | AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES | Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,080,580
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 2728 | Start Trial | |||
| Argentina | 073138 | Start Trial | |||
| Austria | 540040 | Start Trial | |||
| Australia | 2009286380 | Start Trial | |||
| Brazil | PI0918841 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
